Cargando…

FDG-PET in presymptomatic C9orf72 mutation carriers

OBJECTIVE: Our aim is to investigate patterns of brain glucose metabolism using fluorodeoxyglucose positron emission tomography (FDG-PET) in presymptomatic carriers of the C9orf72 repeat expansion to better understand the early preclinical stages of frontotemporal dementia (FTD). METHODS: Structural...

Descripción completa

Detalles Bibliográficos
Autores principales: Popuri, Karteek, Beg, Mirza Faisal, Lee, Hyunwoo, Balachandar, Rakesh, Wang, Lei, Sossi, Vesna, Jacova, Claudia, Baker, Matt, Shahinfard, Elham, Rademakers, Rosa, Mackenzie, Ian R.A., Hsiung, Ging-Yuek R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8170157/
https://www.ncbi.nlm.nih.gov/pubmed/34049163
http://dx.doi.org/10.1016/j.nicl.2021.102687
_version_ 1783702179539845120
author Popuri, Karteek
Beg, Mirza Faisal
Lee, Hyunwoo
Balachandar, Rakesh
Wang, Lei
Sossi, Vesna
Jacova, Claudia
Baker, Matt
Shahinfard, Elham
Rademakers, Rosa
Mackenzie, Ian R.A.
Hsiung, Ging-Yuek R.
author_facet Popuri, Karteek
Beg, Mirza Faisal
Lee, Hyunwoo
Balachandar, Rakesh
Wang, Lei
Sossi, Vesna
Jacova, Claudia
Baker, Matt
Shahinfard, Elham
Rademakers, Rosa
Mackenzie, Ian R.A.
Hsiung, Ging-Yuek R.
author_sort Popuri, Karteek
collection PubMed
description OBJECTIVE: Our aim is to investigate patterns of brain glucose metabolism using fluorodeoxyglucose positron emission tomography (FDG-PET) in presymptomatic carriers of the C9orf72 repeat expansion to better understand the early preclinical stages of frontotemporal dementia (FTD). METHODS: Structural MRI and FDG-PET were performed on clinically asymptomatic members of families with FTD caused by the C9orf72 repeat expansion (15 presymptomatic mutation carriers, C9orf72+; 20 non-carriers, C9orf72-). Regional glucose metabolism in cerebral and cerebellar gray matter was compared between groups. RESULTS: The mean age of the C9orf72+ and C9orf72- groups were 45.3 ± 10.6 and 56.0 ± 11.0 years respectively, and the mean age of FTD onset in their families was 56 ± 7 years. Compared to non-carrier controls, the C9orf72+ group exhibited regional hypometabolism, primarily involving the cingulate gyrus, frontal and temporal neocortices (left > right) and bilateral thalami. CONCLUSIONS: The C9orf72 repeat expansion is associated with changes in brain glucose metabolism that are demonstrable up to 10 years prior to symptom onset and before changes in gray matter volume become significant. These findings indicate that FDG-PET may be a particularly sensitive and useful method for investigating and monitoring the earliest stages of FTD in individuals with this underlying genetic basis.
format Online
Article
Text
id pubmed-8170157
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-81701572021-06-09 FDG-PET in presymptomatic C9orf72 mutation carriers Popuri, Karteek Beg, Mirza Faisal Lee, Hyunwoo Balachandar, Rakesh Wang, Lei Sossi, Vesna Jacova, Claudia Baker, Matt Shahinfard, Elham Rademakers, Rosa Mackenzie, Ian R.A. Hsiung, Ging-Yuek R. Neuroimage Clin Regular Article OBJECTIVE: Our aim is to investigate patterns of brain glucose metabolism using fluorodeoxyglucose positron emission tomography (FDG-PET) in presymptomatic carriers of the C9orf72 repeat expansion to better understand the early preclinical stages of frontotemporal dementia (FTD). METHODS: Structural MRI and FDG-PET were performed on clinically asymptomatic members of families with FTD caused by the C9orf72 repeat expansion (15 presymptomatic mutation carriers, C9orf72+; 20 non-carriers, C9orf72-). Regional glucose metabolism in cerebral and cerebellar gray matter was compared between groups. RESULTS: The mean age of the C9orf72+ and C9orf72- groups were 45.3 ± 10.6 and 56.0 ± 11.0 years respectively, and the mean age of FTD onset in their families was 56 ± 7 years. Compared to non-carrier controls, the C9orf72+ group exhibited regional hypometabolism, primarily involving the cingulate gyrus, frontal and temporal neocortices (left > right) and bilateral thalami. CONCLUSIONS: The C9orf72 repeat expansion is associated with changes in brain glucose metabolism that are demonstrable up to 10 years prior to symptom onset and before changes in gray matter volume become significant. These findings indicate that FDG-PET may be a particularly sensitive and useful method for investigating and monitoring the earliest stages of FTD in individuals with this underlying genetic basis. Elsevier 2021-04-25 /pmc/articles/PMC8170157/ /pubmed/34049163 http://dx.doi.org/10.1016/j.nicl.2021.102687 Text en © 2021 Published by Elsevier Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Regular Article
Popuri, Karteek
Beg, Mirza Faisal
Lee, Hyunwoo
Balachandar, Rakesh
Wang, Lei
Sossi, Vesna
Jacova, Claudia
Baker, Matt
Shahinfard, Elham
Rademakers, Rosa
Mackenzie, Ian R.A.
Hsiung, Ging-Yuek R.
FDG-PET in presymptomatic C9orf72 mutation carriers
title FDG-PET in presymptomatic C9orf72 mutation carriers
title_full FDG-PET in presymptomatic C9orf72 mutation carriers
title_fullStr FDG-PET in presymptomatic C9orf72 mutation carriers
title_full_unstemmed FDG-PET in presymptomatic C9orf72 mutation carriers
title_short FDG-PET in presymptomatic C9orf72 mutation carriers
title_sort fdg-pet in presymptomatic c9orf72 mutation carriers
topic Regular Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8170157/
https://www.ncbi.nlm.nih.gov/pubmed/34049163
http://dx.doi.org/10.1016/j.nicl.2021.102687
work_keys_str_mv AT popurikarteek fdgpetinpresymptomaticc9orf72mutationcarriers
AT begmirzafaisal fdgpetinpresymptomaticc9orf72mutationcarriers
AT leehyunwoo fdgpetinpresymptomaticc9orf72mutationcarriers
AT balachandarrakesh fdgpetinpresymptomaticc9orf72mutationcarriers
AT wanglei fdgpetinpresymptomaticc9orf72mutationcarriers
AT sossivesna fdgpetinpresymptomaticc9orf72mutationcarriers
AT jacovaclaudia fdgpetinpresymptomaticc9orf72mutationcarriers
AT bakermatt fdgpetinpresymptomaticc9orf72mutationcarriers
AT shahinfardelham fdgpetinpresymptomaticc9orf72mutationcarriers
AT rademakersrosa fdgpetinpresymptomaticc9orf72mutationcarriers
AT mackenzieianra fdgpetinpresymptomaticc9orf72mutationcarriers
AT hsiunggingyuekr fdgpetinpresymptomaticc9orf72mutationcarriers